KR101736521B1 - 퀴나졸린 화합물 - Google Patents
퀴나졸린 화합물 Download PDFInfo
- Publication number
- KR101736521B1 KR101736521B1 KR1020127014231A KR20127014231A KR101736521B1 KR 101736521 B1 KR101736521 B1 KR 101736521B1 KR 1020127014231 A KR1020127014231 A KR 1020127014231A KR 20127014231 A KR20127014231 A KR 20127014231A KR 101736521 B1 KR101736521 B1 KR 101736521B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- methyl
- benzenesulfonamide
- quinazolinyl
- methyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AQSFJSXSHHVVPT-UHFFFAOYSA-N CC(C)Oc(c([N+]([O-])=O)c1)ccc1S(NC)(=O)=O Chemical compound CC(C)Oc(c([N+]([O-])=O)c1)ccc1S(NC)(=O)=O AQSFJSXSHHVVPT-UHFFFAOYSA-N 0.000 description 1
- NFUZPVIWFUFFJA-UHFFFAOYSA-N CC(C)Oc(ccc(S(NC)(=O)=O)c1)c1N Chemical compound CC(C)Oc(ccc(S(NC)(=O)=O)c1)c1N NFUZPVIWFUFFJA-UHFFFAOYSA-N 0.000 description 1
- OQHRVARQAYXXKB-UHFFFAOYSA-N CNS(c(cc1)cc(Nc2c(cc(cc3)N)c3ncn2)c1N(C)C)(=O)=O Chemical compound CNS(c(cc1)cc(Nc2c(cc(cc3)N)c3ncn2)c1N(C)C)(=O)=O OQHRVARQAYXXKB-UHFFFAOYSA-N 0.000 description 1
- OEYOZBYTLZVZFT-UHFFFAOYSA-N CNS(c(cc1)cc(Nc2c(cc(cc3)[N+]([O-])=O)c3ncn2)c1N(C)C)(=O)=O Chemical compound CNS(c(cc1)cc(Nc2c(cc(cc3)[N+]([O-])=O)c3ncn2)c1N(C)C)(=O)=O OEYOZBYTLZVZFT-UHFFFAOYSA-N 0.000 description 1
- YZXJNXXOESJUDW-UHFFFAOYSA-N CNS(c(cc1)cc(Nc2c3c(OC)cc(OC)cc3ncn2)c1S(C)(=O)=O)(=O)=O Chemical compound CNS(c(cc1)cc(Nc2c3c(OC)cc(OC)cc3ncn2)c1S(C)(=O)=O)(=O)=O YZXJNXXOESJUDW-UHFFFAOYSA-N 0.000 description 1
- IAWACGQFSRGVHG-UHFFFAOYSA-N CNS(c(cc1)cc(Nc2c3c(OC)cc(OC)cc3ncn2)c1SC)(=O)=O Chemical compound CNS(c(cc1)cc(Nc2c3c(OC)cc(OC)cc3ncn2)c1SC)(=O)=O IAWACGQFSRGVHG-UHFFFAOYSA-N 0.000 description 1
- PRTLSVYSOPRSIX-UHFFFAOYSA-N CNS(c(cc1[N+]([O-])=O)ccc1F)(=O)=O Chemical compound CNS(c(cc1[N+]([O-])=O)ccc1F)(=O)=O PRTLSVYSOPRSIX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25764609P | 2009-11-03 | 2009-11-03 | |
| US61/257,646 | 2009-11-03 | ||
| PCT/US2010/054927 WO2011056740A1 (en) | 2009-11-03 | 2010-11-01 | Quinazoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120112441A KR20120112441A (ko) | 2012-10-11 |
| KR101736521B1 true KR101736521B1 (ko) | 2017-05-16 |
Family
ID=43970282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127014231A Expired - Fee Related KR101736521B1 (ko) | 2009-11-03 | 2010-11-01 | 퀴나졸린 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8859571B2 (https=) |
| EP (1) | EP2501233B1 (https=) |
| JP (1) | JP5836963B2 (https=) |
| KR (1) | KR101736521B1 (https=) |
| CN (1) | CN102711474B (https=) |
| AU (1) | AU2010315361B2 (https=) |
| BR (1) | BR112012010524A2 (https=) |
| CA (1) | CA2779989A1 (https=) |
| EA (1) | EA021439B1 (https=) |
| ES (1) | ES2523465T3 (https=) |
| IL (1) | IL219504A (https=) |
| MX (1) | MX2012005155A (https=) |
| WO (1) | WO2011056740A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5603883B2 (ja) * | 2009-02-17 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体 |
| CN103159685A (zh) * | 2013-04-11 | 2013-06-19 | 苏州立新制药有限公司 | 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法 |
| JP6527513B2 (ja) * | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
| CN105849044B (zh) | 2013-12-26 | 2018-10-26 | 埃克森美孚研究工程公司 | Zsm-48晶体的合成 |
| CN111868039A (zh) * | 2017-09-26 | 2020-10-30 | 加利福尼亚大学董事会 | 用于治疗癌症的组合物和方法 |
| JP7785663B2 (ja) | 2019-09-16 | 2025-12-15 | ノバルティス アーゲー | 二機能性分解誘導薬及びそれらの使用方法 |
| WO2023049312A1 (en) | 2021-09-23 | 2023-03-30 | Erasca, Inc. | Egfr inhibitor polymorph forms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070259904A1 (en) | 2005-11-01 | 2007-11-08 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
-
2010
- 2010-11-01 AU AU2010315361A patent/AU2010315361B2/en not_active Ceased
- 2010-11-01 JP JP2012537925A patent/JP5836963B2/ja not_active Expired - Fee Related
- 2010-11-01 ES ES10828947.1T patent/ES2523465T3/es active Active
- 2010-11-01 KR KR1020127014231A patent/KR101736521B1/ko not_active Expired - Fee Related
- 2010-11-01 CN CN201080060451.4A patent/CN102711474B/zh not_active Expired - Fee Related
- 2010-11-01 EA EA201290243A patent/EA021439B1/ru not_active IP Right Cessation
- 2010-11-01 CA CA2779989A patent/CA2779989A1/en not_active Abandoned
- 2010-11-01 BR BR112012010524A patent/BR112012010524A2/pt not_active IP Right Cessation
- 2010-11-01 EP EP10828947.1A patent/EP2501233B1/en active Active
- 2010-11-01 US US13/505,324 patent/US8859571B2/en not_active Expired - Fee Related
- 2010-11-01 MX MX2012005155A patent/MX2012005155A/es active IP Right Grant
- 2010-11-01 WO PCT/US2010/054927 patent/WO2011056740A1/en not_active Ceased
-
2012
- 2012-04-30 IL IL219504A patent/IL219504A/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070259904A1 (en) | 2005-11-01 | 2007-11-08 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2523465T3 (es) | 2014-11-26 |
| US8859571B2 (en) | 2014-10-14 |
| JP2013510155A (ja) | 2013-03-21 |
| JP5836963B2 (ja) | 2015-12-24 |
| CA2779989A1 (en) | 2011-05-12 |
| US20120220588A1 (en) | 2012-08-30 |
| EP2501233A1 (en) | 2012-09-26 |
| EA201290243A1 (ru) | 2012-12-28 |
| CN102711474A (zh) | 2012-10-03 |
| IL219504A (en) | 2016-09-29 |
| BR112012010524A2 (pt) | 2017-12-12 |
| KR20120112441A (ko) | 2012-10-11 |
| EP2501233B1 (en) | 2014-09-24 |
| WO2011056740A1 (en) | 2011-05-12 |
| MX2012005155A (es) | 2012-08-31 |
| CN102711474B (zh) | 2014-09-10 |
| AU2010315361A1 (en) | 2012-05-24 |
| AU2010315361B2 (en) | 2014-06-12 |
| EA021439B1 (ru) | 2015-06-30 |
| IL219504A0 (en) | 2012-06-28 |
| EP2501233A4 (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101736521B1 (ko) | 퀴나졸린 화합물 | |
| RU2649001C1 (ru) | Производные 2,4-дизамещенного фенилен-1,5-диамина и их применения, фармацевтические композиции и фармацевтически приемлемые композиции, полученные из них | |
| KR101501299B1 (ko) | 신규한 디벤질아민 구조를 갖는 피리미딘 화합물 및 이것을 함유하는 의약 | |
| KR20120114355A (ko) | 화합물 및 방법 | |
| KR20100051814A (ko) | Ｇｐｒ１１９ ｇ 단백질-커플링된 수용체의 조절 방법 및 선택된 화합물 | |
| CN102264707A (zh) | 新型双环型杂环化合物 | |
| JP2008514643A (ja) | 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物 | |
| JPWO2006043490A1 (ja) | 非芳香環縮合ピリミジン誘導体 | |
| CA2870062A1 (en) | Pyrrolopyrazone inhibitors of tankyrase | |
| JPWO2015022926A1 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
| JP6698633B2 (ja) | 複素環化合物 | |
| JPWO2007114323A1 (ja) | アミノピロリジン化合物 | |
| WO2011056739A1 (en) | Compounds and methods | |
| WO2017126635A1 (ja) | 複素環化合物およびその用途 | |
| ES2593057B1 (es) | Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol | |
| US20120157482A1 (en) | Compounds and methods | |
| EP3554504B1 (en) | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof | |
| WO2011088031A1 (en) | Compounds and methods | |
| CN113943251B (zh) | 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途 | |
| WO2019141096A1 (zh) | 取代脲类化合物及其制备方法和用途 | |
| AU2014269229A1 (en) | Bicyclic derivative containing pyrimidine ring, and preparation method therefor | |
| KR20050073241A (ko) | 몰폴린기가 치환된 퀴나졸린 유도체와 이의 제조방법 | |
| KR20050110439A (ko) | 퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20200511 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20200511 |